551 related articles for article (PubMed ID: 16424063)
41. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
Loeb S; Roehl KA; Nadler RB; Yu X; Catalona WJ
J Urol; 2007 Dec; 178(6):2348-52; discussion 2352-3. PubMed ID: 17936844
[TBL] [Abstract][Full Text] [Related]
42. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
43. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
44. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.
Adhami VM; Malik A; Zaman N; Sarfaraz S; Siddiqui IA; Syed DN; Afaq F; Pasha FS; Saleem M; Mukhtar H
Clin Cancer Res; 2007 Mar; 13(5):1611-9. PubMed ID: 17332308
[TBL] [Abstract][Full Text] [Related]
45. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
46. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
[TBL] [Abstract][Full Text] [Related]
47. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
[TBL] [Abstract][Full Text] [Related]
48. Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails.
Rosario DJ; Phillips JT; Chapple CR
J Urol; 2007 Mar; 177(3):1047-51; discussion 1051. PubMed ID: 17296409
[TBL] [Abstract][Full Text] [Related]
49. Correlation of prostate volume with international prostate symptom score and quality of life in men with benign prostatic hyperplasia.
Agrawal CS; Chalise PR; Bhandari BB
Nepal Med Coll J; 2008 Jun; 10(2):104-7. PubMed ID: 18828432
[TBL] [Abstract][Full Text] [Related]
50. ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer.
Lane JA; Er V; Avery KNL; Horwood J; Cantwell M; Caro GP; Crozier A; Smith GD; Donovan JL; Down L; Hamdy FC; Gillatt D; Holly J; Macefield R; Moody H; Neal DE; Walsh E; Martin RM; Metcalfe C
Cancer Prev Res (Phila); 2018 Nov; 11(11):687-696. PubMed ID: 30309839
[TBL] [Abstract][Full Text] [Related]
51. PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy.
Morote J; Fernández S; Alaña L; Iglesias C; Planas J; Reventós J; Ramón Y Cajal S; Paciucci R; de Torres IM
Clin Cancer Res; 2008 May; 14(9):2617-22. PubMed ID: 18451224
[TBL] [Abstract][Full Text] [Related]
52. The natural history of benign prostatic hyperplasia.
Fitzpatrick JM
BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
[TBL] [Abstract][Full Text] [Related]
53. Synergistic effects of multiple treatments, and both DNA and RNA direct bindings on, green tea catechins.
Kuzuhara T; Tanabe A; Sei Y; Yamaguchi K; Suganuma M; Fujiki H
Mol Carcinog; 2007 Aug; 46(8):640-5. PubMed ID: 17440927
[TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of alpha-methylacyl-coA racemase among men with high grade prostatic intraepithelial neoplasia in prostate biopsies.
Stewart J; Fleshner N; Cole H; Toi A; Sweet J
J Urol; 2008 May; 179(5):1751-5; discussion 1755. PubMed ID: 18343427
[TBL] [Abstract][Full Text] [Related]
55. Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial.
Nickel JC; Roehrborn CG; O'leary MP; Bostwick DG; Somerville MC; Rittmaster RS
J Urol; 2007 Sep; 178(3 Pt 1):896-900; discussion 900-1. PubMed ID: 17632164
[TBL] [Abstract][Full Text] [Related]
56. [The PCPT trial].
Hamdy FC; Rouprêt M
Prog Urol; 2008 Apr; 18 Suppl 3():S40-3. PubMed ID: 18455082
[TBL] [Abstract][Full Text] [Related]
57. The effect of dutasteride on the efficacy of photoselective vaporization of the prostate: results of a randomized, placebo-controlled, double-blind study (DOP trial).
Bepple JL; Barone BB; Eure G
Urology; 2009 Nov; 74(5):1101-4. PubMed ID: 19800668
[TBL] [Abstract][Full Text] [Related]
58. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia].
Xu J; Qian WQ; Song JD
Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754
[TBL] [Abstract][Full Text] [Related]
59. Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial.
Low BY; Liong ML; Yuen KH; Chee C; Leong WS; Chong WL; Khan NA; Cheah PY; Liong KK
J Urol; 2008 Apr; 179(4):1461-9. PubMed ID: 18295277
[TBL] [Abstract][Full Text] [Related]
60. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study.
Falahatkar S; Mokhtari G; Pourreza F; Asgari SA; Kamran AN
Urology; 2008 Oct; 72(4):813-6. PubMed ID: 18692876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
